Why you should donate blood

•Download as PPTX, PDF•

1 like•145 views

Donating blood is important because most people will need blood transfusions at some point, either for themselves or loved ones, yet only a small percentage of people donate voluntarily. Donating blood helps save lives since blood cannot be artificially made and has a limited shelf life, so more regular donors are needed to meet the demand.

Health & Medicine

Why you should donate
blood
By Valentina Pernarcic and Renata Marty

Will need blood for themselves or their environment at
some point in their life.
9 out of 10 people
but...
Only 650.000 people out of 45.000.000 donate blood
voluntarily.

There is no way to make artificial blood

Recently uploaded

TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...

kevinkariuki227

Retinal consideration in cataract surgery

KafrELShiekh University

TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...

kevinkariuki227

Blue Printing in medical education by Dr.Mumtaz Ali.pptx

Neurosurgeon Mumtaz Ali Narejo

Gauri Gawande(9) Constipation Final.pptx

gauripg8

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Oleg Kshivets

Why invest into infodemic management in health emergencies

Tina Purnat

Contact dermaititis (irritant and allergic).pdf

Chulalongkorn Allergy and Clinical Immunology Research Group

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

drwaque

Factors Affecting child behavior in Pediatric Dentistry

Dr Simran Deepak Vangani

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

i3 Health

Aptopadesha Pramana / Pariksha: The Verbal Testimony

Dr KHALID B.M

Anti ulcer drugs and their Advance pharmacology || Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining. ||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.

Antiulcer drugs Advance Pharmacology .pptx

Rohit chaurpagar

The hemodynamic and autonomic determinants of elevated blood pressure in obes...

Catherine Liao

Call 0554134915 Or WhatsApp 0555323376 Original 180-hour Power Capsules This product is prepared from pure natural plants extract formula. Take it 2–3 days, increase sexual ability, improve erection hard, which efficacy can last up to 7days if continue to take 1–2 course of treatment, the body system will recovery young state. Penis will be erect, harder & , sexual time will be longer, you always be powerful. If you take long time, you will be like a motor, can never stop and could make love any time as you want. Male enhancement long lasting erection make the penis thicker and longer increase firmer erection heightens orgasmic intensity improve libido and stamina heightens sexual satisfaction.

180-hour Power Capsules For Men In Ghana

healthwatchghana

Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx

Dr. Rabia Inam Gandapore

PFME in supine, sitting, kneeling, and standing positions, which follow by an increase number of contractions and duration of holding. The exercise regimen of holding went from 4 seconds to 30–40 seconds. The contractions will be increased up to 20 contractions as progression. CORE MUSCLE Strengthening The patient will be instructed to work on the transverse abdominis muscle (core muscle). They will be instructed to contract the pelvic floor as above and keep the PFM relaxed.

PT MANAGEMENT OF URINARY INCONTINENCE.pptx

drtabassum4

Antiplatelets in IHD, Dose Duration, DAPT vs SAPT

AkashGanganePatil1

PT MANAGEMENT OF URINARY INCONTINENCE.pptx

drtabassum4

Fundamental of Radiobiology -SABBU.pptx

Sabbu Khatoon

Recently uploaded (20)

TEST BANK For Williams' Essentials of Nutrition and Diet Therapy, 13th Editio...

Retinal consideration in cataract surgery

TEST BANK For Wong’s Essentials of Pediatric Nursing, 11th Edition by Marilyn...

Blue Printing in medical education by Dr.Mumtaz Ali.pptx

Gauri Gawande(9) Constipation Final.pptx

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Why invest into infodemic management in health emergencies

Contact dermaititis (irritant and allergic).pdf

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

Factors Affecting child behavior in Pediatric Dentistry

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

Aptopadesha Pramana / Pariksha: The Verbal Testimony

Antiulcer drugs Advance Pharmacology .pptx

The hemodynamic and autonomic determinants of elevated blood pressure in obes...

180-hour Power Capsules For Men In Ghana

Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx

PT MANAGEMENT OF URINARY INCONTINENCE.pptx

Antiplatelets in IHD, Dose Duration, DAPT vs SAPT

PT MANAGEMENT OF URINARY INCONTINENCE.pptx

Fundamental of Radiobiology -SABBU.pptx